GFAP and dementia: In the context of chronic CNS injury, such as dementia, elevation of plasma GFAP levels begins 10–20 years prior to the onset of symptoms and neurodegeneration, and this rise in GFAP concentration continues throughout the dementia continuum (Chatterjee et al., 2023; Guo et al., 2024; Montoliu‐Gaya et al., 2023).